Researchers identify a way to accelerate "handbrake" immune cells to remove disease faster

Researchers at WEHI have discovered a mechanism to boost immune cells, allowing them to remove disease and infections more quickly.

Researchers identify a way to accelerate ‘handbrake’ immune cells to remove disease faster
L-R: Professor Marc Pellegrini, Associate Professor Daniel Gray, and Dr Charis The. Image Credit: Walter and Eliza Hall Institute.

T cells are immune cells that help in the fight against disease by identifying and killing disease-causing cells.

T cells are held in check by regulatory T cells, or Treg cells, which prevent them from misbehaving and targeting the body’s healthy organs.

Scientists have now identified a technique to purposely throw Treg cells into overdrive by releasing their “handbrake” grip on regular T cells.

Lifting this restriction might boost T cell response and lead to better cancer and infection therapy choices since patients would gain from faster clearance of harmful cells.

Image Credit: Design_Cells/Shutterstock.com

Image Credit: Design_Cells/Shutterstock.com

The study was reported in Science Immunology by Dr Charis Teh, Associate Professor Daniel Gray, Simon Preston, and Professor Marc Pellegrini.

At a glance

  • T cells were allowed to go into speed and increase the immunological response by removing the regulatory “handbrake.”
  • The results provide light on how T cells might be controlled to tackle diseases like cancer and viruses while avoiding autoimmune disorders like multiple sclerosis and diabetes
  • Scientists have found a mechanism to boost T cell responses, which might be used to speed up the healing of infections and cancers.

Boosted response

To investigate the significance of an enzyme in the immune response, the researchers inhibited its activity in Treg cells.

Scientists discovered that the enzyme caspase-8 regulated Treg cell survival in a way that was dependent on the immunological environment.

Treg cells were able to survive and proliferate when the enzyme was inhibited in healthy environments. However, blocking caspase-8 in Treg cells through an infection resulted in necroptosis, a kind of cell death.

Inhibiting caspase-8 in Treg cells, according to Associate Professor Daniel Gray, is a vital step in releasing Treg cells’ constraints on T cells.

Releasing this “handbrake” would greatly assist patients fighting certain debilitating conditions, such as chronic infections, as the T cells are then able to work overtime to drive the infection down or away. But there is a risk when too many Treg cells die, as this can lead to autoimmune conditions like diabetes and multiple sclerosis.”

Daniel Gray, Associate Professor, Joint Division Head, Division of Immunology, Walter and Eliza Hall Institute of Medical Research 

Associate Professor Daniel Gray added, “Knowing where the immune response can be supercharged to a level that will boost immunity, but not cause autoimmune disease, will be integral to advancing new immunotherapies in the future. Our research findings bring the scientific field closer to establishing this threshold.

A therapeutic window

The scientists found that human Treg cells were destroyed more quickly than regular T cells after testing a clinically authorized drug on them. This research found a “therapeutic window” in which Treg cells may be killed while regular T cells were spared.

If we were to target caspase-8 in Treg cells correctly, we could temporarily reduce their suppression on the immune system to enable better defense against certain infections and cancers. Our findings have revealed a new role for this enzyme that could be exploited to fine tune the balance of the immune response to pathogens, cancer, and healthy, normal cells.”

Dr Charis Teh, Division of Immunology, Walter and Eliza Hall Institute of Medical Research

Source:
Journal reference:

Teh, C. E., et al. (2022) Caspase-8 has dual roles in regulatory T cell homeostasis balancing immunity to infection and collateral inflammatory damage. Science Immunology. doi.org/10.1126/sciimmunol.abn8041.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Walter and Eliza Hall Institute of Medical Research (WEHI). (2022, December 19). Researchers identify a way to accelerate "handbrake" immune cells to remove disease faster. AZoLifeSciences. Retrieved on October 10, 2024 from https://www.azolifesciences.com/news/20220415/Researchers-identify-a-way-to-accelerate-handbrake-immune-cells-to-remove-disease-faster.aspx.

  • MLA

    Walter and Eliza Hall Institute of Medical Research (WEHI). "Researchers identify a way to accelerate "handbrake" immune cells to remove disease faster". AZoLifeSciences. 10 October 2024. <https://www.azolifesciences.com/news/20220415/Researchers-identify-a-way-to-accelerate-handbrake-immune-cells-to-remove-disease-faster.aspx>.

  • Chicago

    Walter and Eliza Hall Institute of Medical Research (WEHI). "Researchers identify a way to accelerate "handbrake" immune cells to remove disease faster". AZoLifeSciences. https://www.azolifesciences.com/news/20220415/Researchers-identify-a-way-to-accelerate-handbrake-immune-cells-to-remove-disease-faster.aspx. (accessed October 10, 2024).

  • Harvard

    Walter and Eliza Hall Institute of Medical Research (WEHI). 2022. Researchers identify a way to accelerate "handbrake" immune cells to remove disease faster. AZoLifeSciences, viewed 10 October 2024, https://www.azolifesciences.com/news/20220415/Researchers-identify-a-way-to-accelerate-handbrake-immune-cells-to-remove-disease-faster.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Genetic flaw shows promise for treating eye disease